The GLP-1 Backlash Is Coming — And Most of the Criticism Misses the Point
As GLP-1 agonists go mainstream, the inevitable backlash has begun. Critics warn of muscle loss, dependency, and 'taking the easy way out.' Some concerns are valid. Most miss the point entirely. Here's my take on what the skeptics get right—and where they go wrong.